Medical System Network (4350) · RiskRestated
Risk of differences between provisional and final purchase prices after a drug price revision
First written in FY2018. 2 of 3 entries say "Restated". Latest entry: FY2022.
3entries
5years
0from disclosures
How it moved
Same theme, other companies
Gap Between Provisional Procurement Prices and Agreed Prices After Drug Price RevisionsA theme 3 companies write about · 3 as a headwind · 0 as a tailwind
2 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2022RestatedAnnual report
「Accordingly, if a material difference arises between the provisional and final prices, it may affect the performance of our group.」
The risk of settlement differences between provisional and final purchase prices after a drug price revision continues. - FY2021RestatedAnnual report
「Accordingly, if a material difference arises between the provisional and final prices, it may affect the performance of our group.」
The risk of settlement differences between provisional and final purchase prices after a drug price revision continues to be described. - FY2018First statedAnnual report
「Accordingly, if a material difference arises between the provisional and final prices, it may affect the performance of our group.」
The risk of settlement differences arising from recording purchases at provisional prices after a drug price revision until final purchase prices are agreed with pharmaceutical wholesalers is newly described.